Nuhey News

We talk about the MARKET

Antiemetic Drugs Market Worth US$ 6489.9 Million by 2028 – COVID-19 Impact and Global Analysis by The Market Reports

An antiemetic drug is a drug that is effective against vomiting and nausea. Antiemetics are typically used to treat motion sickness and the side effects of opioid analgesics, general anaesthetics, antipsychotic medication and chemotherapy directed against cancer.

Due to the COVID-19 pandemic, the global Antiemetic Drugs market size is estimated to be worth US$ 4755.6 million in 2021 and is forecast to a readjusted size of US$ 6489.9 million by 2028 with a CAGR of 4.5% during the forecast period 2022-2028. Fully considering the economic change by this health crisis, the Europe Antiemetic Drugs market is estimated at US$ million in 2022, while the United States and China are forecast to reach US$ million and US$ million by 2028, respectively. The proportion of the United States is % in 2022, while Chinese percentage is %, and it is predicted that China market share will reach % in 2028, trailing a CAGR of % through the analysis period. As for the Europe Antiemetic Drugs landscape, Germany is projected to reach US$ million by 2028. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.

The adoption of inorganic growth strategies including M&As, partnerships, and regional acquisition, result in improved market penetration of the vendors. Technological advancements result in improvement and expansion of the product portfolio and R&D advancements. Collaborations or acquisitions of the regional players or the complete acquisition of products will contribute to the growth of the antiemetic drug market as it expands the geographical presence of the acquiring vendor.

This report focuses on Antiemetic Drugs volume and value at the global level, regional level, and company level. From a global perspective, this report represents overall Antiemetic Drugs market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan, etc.

Request for a free sample or purchase this report at:

The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2017 to 2028. Understanding the segments helps in identifying the importance of different factors that aid the market growth.

Segment by Type

  • Dopamine Antagonist
  • 5-HT-3 Receptor Antagonist
  • NK1 Receptor Antagonist
  • Cannabinoid Receptor Antagonist

Segment by Application

  • Chemotherapy
  • Gastroenteritis
  • Surgery

By Company

  • GlaxoSmithKline
  • Johnson & Johnson
  • Pfizer
  • Sanofi
  • Abbott
  • Bristol-Myers Squibb
  • Cipla
  • Eisai
  • Eli Lilly
  • Glenmark
  • Helsinn Healthcare
  • Heron Therapeutics
  • IPCA Laboratories
  • Lupin
  • Merck
  • Novartis
  • RedHill
  • Sun Pharmaceutical Industries
  • Takeda Pharmaceutical

Production by Region

  • North America
  • Europe
  • China

Consumption by Region

  • North America (United States, Canada)
  • Europe (Germany, France, U.K., Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, India, Australia, China Taiwan, Indonesia, Thailand, Malaysia)
  • Latin America (Mexico, Brazil, Argentina)
  • Middle East & Africa (Turkey, Saudi Arabia, UAE)


Contact Details:

Mr. Shirish Gupta

Sales Manager

The Market Reports | Industry and Market Reports at its Best

Call: +1-631-407-1315 / +91-750-729-1479